Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs

@article{Dranitsaris2018CostEV,
  title={Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs},
  author={G. Dranitsaris and X. Zhu and G. Adunlin and M. Vincent},
  journal={Expert Review of Pharmacoeconomics \& Outcomes Research},
  year={2018},
  volume={18},
  pages={351 - 357}
}
ABSTRACT Introduction: After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity and improved quality-of-life. Using the immune system to treat cancer is known as ‘Immuno-oncology’ (IO) and agents are sub-classified by their ability to enhance anti-tumor response or to direct the immune system to attack cancer cells via tumor… Expand
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.
Immunotherapy and urothelial carcinoma: An overview and future prospectives.
The Immunoscore: Colon Cancer and Beyond
...
1
2
3
...

References

SHOWING 1-10 OF 55 REFERENCES
Immuno-regulatory antibodies for the treatment of cancer
Victories and deceptions in tumor immunology
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Improved survival with ipilimumab in patients with metastatic melanoma.
...
1
2
3
4
5
...